Literature DB >> 19245660

The purine nucleosides adenosine and guanosine delay axonal degeneration in vitro.

Craig Press1, Jeffrey Milbrandt.   

Abstract

Axonal degeneration is a key component of many neurodegenerative diseases. Injured axons undergo a program of self-destruction termed Wallerian degeneration that is an active, well-regulated process. The pathways leading to axon fragmentation are uncharacterized, but experiments with wld(s) mutant mice led to the discovery that over-expression of NMN adenylyltransferase 1 or treatment with NAD(+) can inhibit axonal degeneration. In this study, we show that the purine nucleosides adenosine and guanosine, but not inosine, inhibit injury-induced axonal degeneration in cultured dorsal root ganglia neurons. Axons can be preserved by adding adenosine within 6 h of the axonal injury. The presence of adenosine was required continuously after the injury to maintain axonal protection. Together these results suggest that adenosine does not alter the neuronal response to injury, but instead inhibits a local axonal pathway necessary for the commitment and/or execution of the axon destructive program.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19245660      PMCID: PMC2682787          DOI: 10.1111/j.1471-4159.2009.06002.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  43 in total

Review 1.  Axonal self-destruction and neurodegeneration.

Authors:  Martin C Raff; Alan V Whitmore; John T Finn
Journal:  Science       Date:  2002-05-03       Impact factor: 47.728

2.  NS21: re-defined and modified supplement B27 for neuronal cultures.

Authors:  Yucui Chen; Beth Stevens; Jufang Chang; Jeffrey Milbrandt; Ben A Barres; Johannes W Hell
Journal:  J Neurosci Methods       Date:  2008-04-01       Impact factor: 2.390

Review 3.  Trophic effects of purines in neurons and glial cells.

Authors:  M P Rathbone; P J Middlemiss; J W Gysbers; C Andrew; M A Herman; J K Reed; R Ciccarelli; P Di Iorio; F Caciagli
Journal:  Prog Neurobiol       Date:  1999-12       Impact factor: 11.685

Review 4.  Adenosine in the central nervous system: release mechanisms and extracellular concentrations.

Authors:  S Latini; F Pedata
Journal:  J Neurochem       Date:  2001-11       Impact factor: 5.372

Review 5.  Tryptophan, adenosine, neurodegeneration and neuroprotection.

Authors:  T W Stone; C M Forrest; G M Mackay; N Stoy; L G Darlington
Journal:  Metab Brain Dis       Date:  2007-12       Impact factor: 3.584

6.  Absence of Wallerian Degeneration does not Hinder Regeneration in Peripheral Nerve.

Authors:  E R Lunn; V H Perry; M C Brown; H Rosen; S Gordon
Journal:  Eur J Neurosci       Date:  1989       Impact factor: 3.386

7.  Quinolinic acid promotes seizures and decreases glutamate uptake in young rats: reversal by orally administered guanosine.

Authors:  Diogo Losch de Oliveira; Joel Felipe Horn; Juliana Moura Rodrigues; Marcos E S Frizzo; Emílio Moriguchi; Diogo Onofre Souza; Susana Wofchuk
Journal:  Brain Res       Date:  2004-08-20       Impact factor: 3.252

8.  Inhibiting axon degeneration and synapse loss attenuates apoptosis and disease progression in a mouse model of motoneuron disease.

Authors:  Anna Ferri; Joshua R Sanes; Michael P Coleman; Jeanette M Cunningham; Ann C Kato
Journal:  Curr Biol       Date:  2003-04-15       Impact factor: 10.834

9.  Delayed synaptic degeneration in the CNS of Wlds mice after cortical lesion.

Authors:  Thomas H Gillingwater; Cali A Ingham; Katherine E Parry; Ann K Wright; Jane E Haley; Thomas M Wishart; Gordon W Arbuthnott; Richard R Ribchester
Journal:  Brain       Date:  2006-06       Impact factor: 13.501

10.  Guanosine reduces apoptosis and inflammation associated with restoration of function in rats with acute spinal cord injury.

Authors:  Shucui Jiang; Farid Bendjelloul; Patrizia Ballerini; Iolanda D'Alimonte; Elenora Nargi; Cai Jiang; Xinjie Huang; Michel P Rathbone
Journal:  Purinergic Signal       Date:  2007-09-25       Impact factor: 3.765

View more
  5 in total

1.  Enhancement of Peripheral Nerve Regrowth by the Purine Nucleoside Analog and Cell Cycle Inhibitor, Roscovitine.

Authors:  Vincent Law; Sophie Dong; Jesusa L Rosales; Myung-Yung Jeong; Douglas Zochodne; Ki-Young Lee
Journal:  Front Cell Neurosci       Date:  2016-10-17       Impact factor: 5.505

2.  Quantification of Neurite Degeneration with Enhanced Accuracy and Efficiency in an In Vitro Model of Parkinson's Disease.

Authors:  Rachel T Clements; Lauren E Fuller; Kyle R Kraemer; Samantha A Radomski; Sarah Hunter-Chang; Wesley C Hall; Alborz A Kalantar; Bradley R Kraemer
Journal:  eNeuro       Date:  2022-03-18

Review 3.  Purine nucleosides: endogenous neuroprotectants in hypoxic brain.

Authors:  Bettina Thauerer; Stephanie Zur Nedden; Gabriele Baier-Bitterlich
Journal:  J Neurochem       Date:  2012-03-14       Impact factor: 5.372

Review 4.  The Guanine-Based Purinergic System: The Tale of An Orphan Neuromodulation.

Authors:  Valentina Di Liberto; Giuseppa Mudò; Roberta Garozzo; Monica Frinchi; Víctor Fernandez-Dueñas; Patrizia Di Iorio; Renata Ciccarelli; Francesco Caciagli; Daniele F Condorelli; Francisco Ciruela; Natale Belluardo
Journal:  Front Pharmacol       Date:  2016-06-17       Impact factor: 5.810

5.  Critical signaling pathways during Wallerian degeneration of peripheral nerve.

Authors:  Qiong Cheng; Ya-Xian Wang; Jun Yu; Sheng Yi
Journal:  Neural Regen Res       Date:  2017-06       Impact factor: 5.135

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.